Open-Label Extension Study of Rufinamide Given as Adjunctive Therapy in Patients With Refractory Partial Seizures

NCT00448539 · clinicaltrials.gov ↗
PHASE3
Phase
TERMINATED
Status
286
Enrollment
INDUSTRY
Sponsor class

Stopped The study was terminated early by the sponsor due to the discontinuation of clinical development for rufinamide.

Conditions

Interventions

Sponsor

Eisai Inc.